Twist Bioscience Co. (NASDAQ:TWST) COO Sells $97,426.49 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,261 shares of the company’s stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49. Following the sale, the chief operating officer now directly owns 159,483 shares of the company’s stock, valued at approximately $6,872,122.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.
• On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total transaction of $115,198.05.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $0.36 during trading on Friday, hitting $40.60. The stock had a trading volume of 593,422 shares, compared to its average volume of 955,359. The firm’s fifty day simple moving average is $43.89 and its 200-day simple moving average is $44.58. The stock has a market cap of $2.36 billion, a PE ratio of -12.08 and a beta of 1.77. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience’s revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.01) EPS. Analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC purchased a new position in Twist Bioscience in the 3rd quarter worth about $416,000. China Universal Asset Management Co. Ltd. increased its stake in Twist Bioscience by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company’s stock worth $509,000 after buying an additional 4,427 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares during the period. International Assets Investment Management LLC increased its stake in Twist Bioscience by 4,418.3% in the 3rd quarter. International Assets Investment Management LLC now owns 4,925 shares of the company’s stock worth $223,000 after buying an additional 4,816 shares during the period. Finally, Signaturefd LLC increased its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.